Answers are grounded in this paper and cite their sources.
Objective: To evaluate the efficacy of Transcranial Magnetic Stimulation (TMS) in gait of patients with Multiple Sclerosis (MS). Background: MS is a neurological disorder characterized by demyelination in the central nervous system, leading to increased muscle tone and motor dysfunction. TMS, a noninvasive technique, is used to stimulate nerve cells and activate specific regions of the brain. Multiple studies suggest TMS may improve motor symptoms, but the evidence quality is low and often insufficient to confirm its benefit. Design/Methods: A systematic search was performed across PubMed, Embase, Web of Science, and Cochrane databases up to September 2024. Studies evaluating the safety and efficacy of TMS on gait were included. The primary outcomes assessed were the Timed Up and Go (TUG) test, the Modified Ashworth Scale (MAS), and the Fatigue Scale. Results: Of the 919 studies screened, seven met the inclusion criteria, including 73 patients with a mean age of 45.7 years. In the evaluation of the Fatigue, being mainly made by the Modified Fatigue Impact Scale (MFIS), has found repetitive TMS as a valid choice to significantly reduce the mean ± SD for this outcome. (Variation post intervention: 3.95± 1.40 a 21.07 ± 10.06). Two measures were used to access balance and gait: the Timed Up and Go (TUG) and Berg Balance Scale (BBS). Across the included studies, the TMS group consistently showed significant improvements in both TUG and BBS scores, indicating enhanced balance and gait capabilities. The Modified Ashworth Scale (MAS) was employed to evaluate spasticity. While a trend towards TMS, were a higher reduction has been seen in some studies, carried out by the comparison with a sham group. Conclusions: This review suggests that TMS may improve gait, balance, and alleviate fatigue in patients with MS. Further large, well-designed trials are needed to confirm these findings and optimize TMS protocols for MS. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Mr. Abraham has nothing to disclose. Miss Silva has nothing to disclose. Dr. De Siqueira Lima has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. De Siqueira Lima has stock in Moderna. Dr. De Siqueira Lima has stock in Johnson & Johnson. Dr. De Siqueira Lima has stock in Pfizer. Mr. De Sousa Marinho Mendes Filho has nothing to disclose. Mr. de Oliveira Ramos has nothing to disclose. Mr. Pedrosa has nothing to disclose. Mr. Filho has nothing to disclose. Dr. Dominici has nothing to disclose. Mrs. de Farias has nothing to disclose. Ms. Capitanio has nothing to disclose. Mr. Corvelo has nothing to disclose. Mr. Geremias has nothing to disclose. Mr. Fukunaga has nothing to disclose. Miss Lima has nothing to disclose. Dr. Reis has nothing to disclose. Dr. OLIVEIRA has nothing to disclose.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: